Less than two weeks after a similar move by Boehringer Ingelheim, AstraZeneca has moved to cap out-of-pocket costs for its inhalers at $35 for certain patients as drug makers face increasing political pressure to lower costs. But the announcement also creates pressure of a sort on the politicians that were leaning on the sponsors: The pricing cannot extend to the Medicare population without Congressional legislation.
Key Takeaways
-
AstraZeneca’s cap on patient cost sharing for its inhaled drugs at $35 for uninsured and commercially insured individuals in the US comes weeks after Boehringer Ingelheim announced a similar plan.
-
The move highlights two rare areas of agreement for the pharmaceutical industry and Democratic politicians: support for copay caps and a distaste for PBM rebating tactics
AstraZeneca said on 18 March that effective 1 June, eligible patients – namely those with commercial insurance and the uninsured – would pay no more than $35 per month in copays for inhalers across its entire inhaled respiratory
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
